This statement provides new recommendations for targeted tuberculin testing and treatment regimens for persons with latent tub activities as an essential component of the TB Elimination Strategy promoted by the U.S. Public Health Service Advisory Coun Centers for Disease Control and Prevention (CDC). Isoniazid for 6--12 mo has been the mainstay of treatment for LTBI in the United States for more than 30 yr. However, the appl of concerns about toxicity. Therefore, there has been interest in the development of shorter, rifampin-based regimens as alternat human immunodeficiency virus (HIV) infection has been undertaken. The results of these trials have recently become available, addition, many changes to previous recommendations regarding testing for and treatment of LTBI are presented (Table 1 ).
Targeted Tuberculin Testing
Targeted tuberculin testing for LTBI is a strategic component of tuberculosis (TB) control that identifies persons at high risk for recent infection with Mycobacterium tuberculosis and those who have clinical conditions that are associated with an increased r only among groups at high risk and discouraged in those at low risk. Infected persons who are considered to be at high risk for d Based on the sensitivity and specificity of the purified protein derivative (PPD) tuberculin skin test and the prevalence of TB in induration (see Table 7 ). For persons who are at highest risk for developing active TB if they are infected with M. tuberculosis ( TB, or who have abnormal chest radiographs consistent with prior TB), >5 mm of induration is considered positive. For other pe mm of induration is considered positive. These include recent immigrants (i.e., within the last 5 yr) from high prevalence countr mycobacteriology laboratory personnel; persons with clinical conditions such as silicosis, diabetes mellitus, chronic renal failure bypass; and children younger than 4 yr of age or infants, children, and adolescents exposed to adults in high-risk categories. For
Treatment of Latent Tuberculosis Infection
In this report, treatment recommendations use an adaptation of the rating system from recent U.S. Public Health Service docume Four regimens are recommended for the treatment of adults with LTBI. (See Tables 8 and 10 for detailed recommendations, dos
The isoniazid daily regimen for 9 mo is recommended because prospective, randomized trials in HIV-negative persons indicate of isoniazid is likely achieved by 9 mo, and minimal additional benefit is gained by extending therapy to 12 mo. When compare each other in randomized trials. Although a 9-mo regimen of isoniazid is the preferred regimen for the treatment of LTBI, a 6-mo regimen also provides substan mo rather than 9 mo may provide a more favorable outcome from a cost-effectiveness standpoint. Thus, based on local conditio Both the 9-mo and 6-mo isoniazid regimens may be given intermittently (i.e., twice weekly). When isoniazid is given intermitte The 2-mo daily regimen of rifampin and pyrazinamide is recommended on the basis of a prospective randomized trial of treatme weekly treatment with rifampin and pyrazinamide for 2 or 3 mo may be considered when alternative regimens cannot be given. pyrazinamide also be given by DOT, which can consist of five observed and two self-administered doses each week. In situation Rifampin given daily for 4 mo is recommended on the basis of the efficacy of a similar regimen in a) a prospective randomized option may be especially useful for patients who cannot tolerate isoniazid or pyrazinamide. Before beginning treatment of LTBI, active TB should be ruled out by history, physical examination, chest radiography, and, wh Special considerations for treatment of LTBI apply to the following populations:
• When isoniazid is chosen for treatment of LTBI in persons with HIV infection or those with radiographic evidence of p • For pregnant, HIV-negative women, isoniazid given daily or twice weekly for 9 or 6 mo is recommended. For women therapy should not be delayed on the basis of pregnancy alone, even during the first trimester. For women whose risk f • For children and adolescents, isoniazid given either daily or twice weekly for 9 mo is the recommended regimen.
• For contacts of patients with isoniazid-resistant, rifampin-susceptible TB, rifampin and pyrazinamide given daily for 2 • For persons who are likely to be infected with isoniazid-and rifampin-resistant (multidrug) TB and who are at high risk recommended. Immunocompetent contacts may be observed or treated for at least 6 mo, and immunocompromised con
Clinical and Laboratory Monitoring
Once patients have been identified and then tested for LTBI, they should receive an initial clinical evaluation. They should also pyrazinamide). This evaluation should include questioning about side effects and a brief physical assessment checking for signs seek medical evaluation when they occur. Baseline laboratory testing is not routinely indicated for all patients at the start of treatment for LTBI (see Table 8 )
. Patients who oxaloacetic transaminase) (AST [SGOT]) or alanine aminotransferase (serum glutamic pyruvic transaminase) (ALT [SGPT]
) an (i.e., within 3 mo of delivery), persons with a history of chronic liver disease (e.g., hepatitis B or C, alcoholic hepatitis, or cirrho However, such testing may be considered on an individual basis, particularly for patients who are taking other medications for c treatment of LTBI. Routine laboratory monitoring during treatment of LTBI is indicated for persons whose baseline liver function tests are abnorma during the course of treatment (e.g., liver function studies for patients with symptoms compatible with hepatotoxicity or a uric a three times the upper limit of normal if associated with symptoms and five times the upper limit of normal if the patient is asym
INTRODUCTION

History of Treatment of Latent Tuberculosis Infection and Relevance to Tuberculosis Control
For more than three decades, treatment of persons with latent Mycobacterium tuberculosis infection (LTBI) to prevent the devel countries with a low incidence of TB, most new, active cases have occurred among persons who were once infected, contained t benefit both infected persons and susceptible persons in their communities. Until recently, isoniazid was the only drug proven ef Shortly after isoniazid was found to be effective for the treatment of TB, clinical trials were begun to assess the ability of the dru to evaluate the drug for treatment of infected contacts of TB patients and of other persons at high risk (e.g., those with radiograp Society (ATS) (7). This initial statement recommended isoniazid for persons with evidence of previously untreated TB and pers and PHS broadened the recommendations to include all persons who had had a purified protein derivative (PPD) tuberculin skin not previously treated and their contacts, b) persons with tuberculin skin test conversions, c) persons with specified medical con drug that had "virtually no side effects," it was believed that "chemoprophylaxis [could] reduce future morbidity from TB in hig However, despite this belief, the goal of reducing TB morbidity by such a substantial percentage through the administration of i Hill in the District of Columbia, 19 persons developed clinical signs of liver disease and two persons died of hepatic failure attri regarding pretreatment screening and monitoring to minimize the risk for severe complications (10) . In 1974, following a study persons aged older than 35 yr of age as candidates for treatment (12) . Subsequent controversy over the appropriate age cut-off for these low-risk, tuberculin-positive persons ensued, with one group c decrease in the use of isoniazid for treating persons with LTBI---even persons at high risk for whom treatment was indicated (14 and other persons at risk for hepatotoxicity (15) . Recent studies have suggested that since the advent of routine monitoring, the r Because widespread use and the potential impact of isoniazid treatment of LTBI became limited by actual and perceived toxicity introduction of rifampin, which appeared to be a better sterilizing agent than isoniazid, suggested the possibility that rifampin-ba evaluate the efficacy of treatment for LTBI in persons coinfected with HIV and M. tuberculosis led to a series of studies of shor substantially to guidelines on treatment of LTBI in persons with HIV infection (3).
Relationship of Tuberculin Testing to Treatment of Latent Tuberculosis Infection
As the rate of active TB in the United States has decreased, identification and treatment of persons with latent infection who are Elimination of Tuberculosis (19). Because testing persons for infection and provision of treatment are interrelated, these recomm recommendations on the use of new, short-course treatment regimens.
Change in Nomenclature
Identification of persons with LTBI has previously been accomplished by widespread tuberculin skin testing of individuals or gr tested. To focus on groups at the highest risk for TB, the term "targeted tuberculin testing" is used in these guidelines to encoura Although the terms "preventive therapy" and "chemoprophylaxis" have been used for decades, they have also been confusing. "P known or likely to be infected with M. tuberculosis, but it rarely results in true primary prevention (i.e., prevention of infection i "treatment of LTBI" rather than "preventive therapy" or "chemoprophylaxis." This change in nomenclature will hopefully prom control strategy. (28) . In a prospective cohort study of persons with HIV infection in the United States, the annual risk of a for progressing to active TB (10 cases per 1000 person-years) (30) , and this risk is even greater for injection drug users coinfect population, and the increased risk associated with injection drug use and HIV infection. The risk for active TB is also increased in a) persons with pulmonary fibrotic lesions seen on chest radiographs (presumed to be risk for progression to active TB of 2.0--13.6 per 1000 person-years of observation (32--34) . A study of 23,541 U.S. Naval recru risk of progression to disease that was twofold that of persons who were within 5% of the standard weight for their height and m Studies indicate that several other clinical conditions increase the risk for active TB, although participants in these studies were Tuberculin-positive persons with silicosis have an approximately 30-fold greater risk for developing TB (36--38) . Persons with with diabetes mellitus have a risk for developing active TB that is twofold to fourfold greater than persons without diabetes mel been associated with active TB include gastrectomy with attendant weight loss and malabsorption (45--47), jejunoileal bypass (4 and leukemia [54] ). Persons receiving prolonged therapy with corticosteroids and other immunosuppressive agents may be at risk for reactivation of (55, 56) , and because lower doses or those given intermittently are not associated with TB, this dose is likely the lower limit that prolonged periods of time, especially in populations at high risk for TB, but specific thresholds of dose and duration that could i other potential risk factors that commonly occur among such persons, alcohol use has been difficult to identify as a separate risk (74) . No reliable method has been dev reactions of >20 mm of induration are not likely caused by BCG (75) .
SCIENTIFIC RATIONALE Targeted Tuberculin Testing
Diagnosis of Latent Tuberculosis Infection
HIV infection and anergy testing. HIV-infected persons may have a compromised ability to react to tuberculin skin tests because tuberculin-negative, HIV-infected persons who might benefit from treatment of LTBI has not been demonstrated (77).
Chest Radiographs
In persons with LTBI, the chest radiograph is usually normal, although it may show abnormalities suggestive of prior TB. Previ with or without visible calcification, may be seen in the hilar area or upper lobes. Smaller nodules, with or without fibrotic scars TB have well-demarcated, sharp margins and are often described as "hard." Bronchiectasis of the upper lobes is a nonspecific fi or other infections. Nodules and fibrotic scars may contain slowly multiplying tubercle bacilli with substantial potential for futu risk for future progression to active TB.
Sputum Examinations
The presumptive diagnosis of active pulmonary TB is often made on the basis of microscopic examination of a stained sputum s persons with normal chest radiographs, AFB are rarely seen on sputum smear examination, and tubercle bacilli are not found in chest radiographs.
Treatment of Latent Tuberculosis Infection
Isoniazid Experimental studies. Before clinical trials of isoniazid for the treatment of LTBI were begun in the United States, its efficacy w tubercle bacilli (78) . Those animals receiving a daily dosage of at least 5 mg/kg were protected (i.e., survival was comparable to humans. Clinical trials in HIV-negative persons. Many randomized, controlled clinical trials of isoniazid for the treatment of LTBI were than 100,000 participants at risk for TB, including children with primary TB, contacts of active case patients, persons who had h isoniazid with placebo. The outcomes measured in these studies included progression of primary TB, tuberculin conversion in u in TB among all persons participating in these trials, varied from 25 to 92%. However, when analysis was restricted to persons w was irregular but sustained, suggesting the possibility that intermittent treatment may be efficacious. Only one trial, conducted by the International Union Against Tuberculosis (IUAT) (32) , was designed to evaluate various durati pulmonary lesions consistent with inactive TB. The 5-yr incidence rates of tuberculosis were 1.43% for placebo compared with regimen and 75% effectiveness for the 12-mo regimen; persons who received 6 mo of isoniazid had a 40% higher risk for TB co The difference in the two regimens is magnified when study subjects who received "almost all" of the monthly drug allotments f subgroup, which constituted 78% of the entire study population, the resulting 5-yr incidence rates were 1.5% for persons receivi 69% efficacious and for 12 mo was 93% efficacious; participants on the 6-mo regimen had a fourfold higher risk for TB than th regimens, such persons were less adherent to treatment. The 12-mo regimen provided a substantial reduction in risk compared w Additional information on the efficacy and effectiveness of different lengths of therapy with isoniazid for the treatment of LTBI assigned medication during the months they took isoniazid, those who took medication for at least 10 mo experienced a 68% red The same data can be further examined to determine whether reduction in the rate of TB was affected more by duration of thera medication during the 10-mo period (52--57% reduction compared to 68% reduction), suggesting that even an intermittent treatm In a community-based study conducted in Bethel, Alaska (79) , persons who took <25% of the prescribed annual dose had a thre decreased significantly if <9 mo of isoniazid was taken ( Figure 1 ) (80) . Effectiveness data from the IUAT study, published data on isoniazid-associated hepatitis, and cost information obtained from a with the 6-mo regimen was determined to be half of the cost as either the 3-mo or 12-mo regimens. This cost-effectiveness analy with normal chest radiographs (82) . However, the protection conferred by taking at least 9 mo of isoniazid is greater than that co Clinical trials in HIV-positive persons. Seven randomized, controlled trials have evaluated different regimens for the treatment o either received a placebo or were not actively treated.
In the first study, conducted in Haiti during 1986--1992, 12 mo of daily isoniazid resulted in a substantial reduction in TB (83% 6 mo of isoniazid taken daily by tuberculin-positive persons, had differing results: the drug provided a significant level of protec weekly regimen of isoniazid in both tuberculin-positive and -negative persons in Zambia (86) . The overall level of protection w because of the limited number of persons in this group. The Uganda study also evaluated the 6-mo regimen of daily isoniazid in anergic persons, as did the fifth study conducted in the Additional evaluations of isoniazid were conducted in tuberculin-negative persons who were not assessed for anergy (83, 85, 86) treatment should be targeted at tuberculin-positive persons. A recently published metaanalysis of these trials supports this concl Safety and tolerability. In 1965, when isoniazid was first recommended in the United States for treatment of LTBI, it was not th suspected drug reactions was low and approximately equivalent for the placebo and isoniazid groups (21) . The occurrence of he hepatitis and indicated that asymptomatic increase in hepatic transaminases occurred among persons receiving the drug (89) . It w understood (9) . The largest and most comprehensive study of isoniazid hepatitis was conducted by PHS during 1971--1972 (11) . In this survey, was 1%, but it was age related, with no cases occurring among persons younger than 20 yr of age and the highest rate (2.3%) oc higher among persons consuming alcohol daily than among those who did not drink alcohol. Rates among males and females w lower among participants in the IUAT trial, although the same positive association with age was observed (32) . In the PHS surv years after completion of the study, a review of death certificates showed a marked increase in deaths from cirrhosis during 197 study (90) . A comprehensive analysis of deaths from isoniazid-associated hepatitis in the United States found that women may be at increas drug to pregnant women in the third trimester and the immediate postpartum period (92) or by the concomitant administration o detailed study of deaths from isoniazid-associated hepatitis did not implicate acetaminophen as a factor (95) . Isoniazid-related deaths continue to be reported. However, the likelihood of this occurrence can be greatly reduced by careful m following the development of fulminant, isoniazid-related hepatitis continued to take the drug for a least 10 d after onset of sym Following the PHS surveillance study, guidelines on the use of isoniazid for the treatment of LTBI were revised to recommend a time, and that monthly questioning and education about signs and symptoms of hepatitis should be routine (12) . The guideline of age or older (15) . More recently, a survey found that many public health TB clinics now use clinical, rather than biochemical, monitoring for hepa instructing them to stop treatment immediately if such symptoms occur and to report to the clinician for evaluation. After using hospitalization) and no deaths among more than 11,000 persons with LTBI during isoniazid treatment over a 7-yr period (99) . B toxicity monitoring "that are congruent with established therapeutic/toxicity relationships" (98) . Recent studies of isoniazid treatment of LTBI in HIV-infected persons have demonstrated that the medication was well tolerated reactions were slightly but not significantly more common among persons receiving isoniazid (88) . Despite the high efficacy and relative safety of isoniazid treatment for LTBI, its use has been frequently debated; much literatur literature emerged more than two decades ago, in a different environmental context with different risks and contingencies, its ap Although the likelihood that a patient treated with isoniazid would develop hepatitis was low, it presented a valid argument agai drug, which appeared from the 1970s through the early 1980s, focused on persons at low risk for reacting to tuberculin, primaril Because the debate over whether to prescribe or withhold isoniazid for persons older than 35 yr of age at low risk for reacting to was used by most investigators (103) . Despite many analyses, the decision to treat persons at low risk for reacting to tuberculin isoniazid was substantial.
Short-course Regimens
Experimental studies in animals. Because of high rates of nonadherence with the long duration of isoniazid (i.e., 6--12 mo) and evaluating rifampin were based on data from several studies in mouse models of chronic TB. One study compared isoniazid wit lung and spleen tissues within 4 mo, and the combination of rifampin and pyrazinamide sterilized tissues within 2 mo. The isoni tissues. The isoniazid regimen had not sterilized tissues by the end of 6 mo. The apparent superiority of the rifampin--pyrazinamide regimen over the regimen containing the same two drugs plus isoniazid came from a study using a Cornell mouse model (106) that compared 6-wk regimens of rifampin, rifampin--isoniazid, rifampinthree regimens was similar, with trend toward a lower colony count in spleens of animals given more drugs, and lower colony c isoniazid, taken twice weekly, may effectively treat LTBI in 3 mo (107).
Clinical trials in HIV-negative persons.
The only randomized clinical trial to evaluate rifampin-containing regimens among HIV isoniazid, 3 mo of rifampin, or 3 mo of isoniazid and rifampin were compared with a 6-mo placebo control. Analyzing only thos the 6-mo isoniazid regimen, and 41% for the 3-mo isoniazid--rifampin regimen. All of these differences were significantly diffe placebo group and about 4% per year in the three active-treatment regimens combined. The largest programmatic experience using rifampin-based treatment of LTBI comes from Blackburn, England, where children shortened from 9 to 3 mo, and the proportion of pediatric TB case patients as a percentage of all reported cases decreased from 2 childhood TB in this city. Thus, this regimen is currently recommended for the treatment of both adults and children with LTBI Clinical trials in HIV-positive persons. Most clinical trials of rifampin-based treatment of LTBI have been conducted among HI rifampin--pyrazinamide taken daily for 3 mo in tuberculin-positive persons (84) . The isoniazid--rifampin regimen provided 59% alone. The Zambia study also evaluated a self-administered regimen of rifampin and pyrazinamide taken twice weekly for 3 mo persons, the level of protection conferred by rifampin and pyrazinamide was 70%, comparable with that conferred by 6 mo of is In two trials, rifampin and pyrazinamide regimens have been compared with regimens of isoniazid alone in tuberculin-positive p pyrazinamide, with half of the doses directly observed (110) . Protection at 12 mo was similar in the two groups, and, compared reduced the risk for TB by approximately 80%. A multinational study comparing a 12-mo regimen of isoniazid taken daily with patients were enrolled and followed for an average of 3 yr. The annual risk of culture-confirmed TB was 0.8% for patients assig In conclusion, as evidenced by the large multinational study, a 2-mo regimen of rifampin and pyrazinamide taken daily provides pyrazinamide treatment regimen are less conclusive. The only study that has evaluated a rifampin-alone regimen, the Hong Kon In the Uganda study, 3-mo regimens of a) isoniazid and rifampin and b) isoniazid, rifampin, and pyrazinamide provided protecti All of the studies of treatment of LTBI in HIV-infected persons included death and/or progression of HIV disease as endpoints. the multinational study, persons receiving the 2-mo regimen had lower mortality rates and less progression of HIV disease, altho progression. Safety and tolerability. Before the conduct of the studies in HIV-infected persons, a pilot study to assess the safety and tolerabili receive either 2 mo of rifampin and pyrazinamide, 4 mo of rifampin only, or 6 mo of isoniazid. The rifampin--pyrazinamide reg isoniazid group) and more frequent adverse reactions resulting in drug discontinuation (15 compared with none in the rifampin g involving HIV-positive populations and those described in a clinical trial of isoniazid, rifampin, and pyrazinamide for the treatm Two smaller pilot studies of rifampin and pyrazinamide treatment of LTBI using identical protocols were conducted in adults in children in Germany tolerated the regimens well and did not experience changes in hepatic function.
In the Hong Kong study of patients with silicosis, no significant differences were noted in the occurrence of severe adverse reac during treatment.
In the clinical trials involving HIV-infected persons, a trend of increased adverse reactions occurred among persons taking a dai higher rates of paresthesias, arthralgias, and significant increases in serum AST (84) . The multinational study reported minimal commonly because of nausea and vomiting and narcotic withdrawal (111) . However, abnormal liver function tests were more co In the Haiti study conducted during 1990--1994 and the Zambia study, regimens of twice-weekly rifampin and pyrazinamide we differ by regimen (110) . In the Zambia study, 3% of persons given isoniazid stopped treatment because of an adverse reaction co was more common in persons receiving rifampin and pyrazinamide. Adherence Testing for and treating LTBI requires several steps, including administering the test, reading the test, medically evaluating infe treatment, nonadherence occurs commonly in all steps of the treatment process. The health care system can compromise patient adherence to testing and treatment of LTBI (117). A lengthy referral process ma also discourage patients from attending follow-up visits. Other factors that may affect adherence with testing and treatment inclu Since the advent of effective chemotherapy for active TB, adherence to treatment regimens has been recognized as a substantial for LTBI complete at least 6 mo of treatment (CDC, TB Program Management Reports); adherence is influenced by the length o the regimen increases with the length of therapy (32) . Patients may be more adherent to the 2-mo regimen of rifampin and pyraz this regimen as well as isoniazid, thus potentially resulting in nonadherence. The Haiti study of rifampin and pyrazinamide taken twice weekly and the multinational study both reported better adherence wi have taken >80% of the prescribed medication compared with 55% of persons taking isoniazid for 6 mo (110). Nonadherence w 2-mo rifampin and pyrazinamide regimen compared with 69% for the 12-mo isoniazid regimen (111) . In the pilot study of HIVnonadherent, compared with about 20% of those assigned to the 6-mo isoniazid regimen (113) . However, overall completion rat Determinants of adherence to treatment of TB and LTBI are not well understood (118). For example, demographic factors are n adversely affect adherence (119) . The main strategies that have been employed to promote adherence with treatment of LTBI ar (122) , and directly observed therapy (DOT) (64) . The intervention most likely to improve adherence for treatment of LTBI has been DOT, which requires direct observation of th needs and the use of incentives and enablers (123--125). Although randomized trials have yet to be reported, available informati (67).
RECOMMENDATIONS Implementation of Targeted Tuberculin Testing
Decision to Tuberculin Test Is Decision to Treat
Targeted tuberculin testing programs should be designed for one purpose: to identify persons at high risk for TB who would ben infection with M. tuberculosis and those who, regardless of duration of infection, are at increased risk for progression to active T employment in a setting where TB transmission may occur), screening of low-risk persons is discouraged because it diverts reso have false-positive skin tests (73) . Testing is also discouraged unless a plan has been developed to complete a course of treatment in persons found to have LTBI. S medical supervision of the course of treatment.
Identification and Access to High-risk Groups
A flexible approach to identifying high-risk groups is recommended, and state and local public health agencies are encouraged t epidemiology of TB. Thus designing and conducting skin-test-screening surveys to determine whether population groups are at community health centers and schools serving foreign-born persons, and selected community-based organizations. Mandated sk groups contain substantial proportions of persons at high risk (126) .
Role of the Health Department
In this community-based approach to targeted testing and treatment of LTBI, the health department TB program should be instru assessing the community's TB problem, identifying high-risk groups based on the local epidemiology of TB, and ascertaining th based approach, recruiting health professionals, educating such professionals about TB, and motivating them to institute targeted institutions that conduct testing and treatment programs. The health department should assist in identifying potential funding sou treatment, written protocols for activities including patient tracking and skin testing, and patient and provider educational materi antituberculosis drugs. Finally, the health department should be responsible for providing or facilitating the ongoing evaluation tests administered that are read, proportion of tests read that are positive, and initiation and completion rates of treatment). The h treatment of LTBI in the community. To achieve a high rate of acceptance of testing and completion of treatment in a community-based program, barriers to success s is unfamiliar to most persons, and education of the patient is essential (120) . Other known barriers include culturally derived hea afford the costs of medical evaluation and treatment, and lack of access to medical care (118). Patients should not be expected to treatment, the more likely patients will adhere to therapyespecially as targeted testing and treatment of LTBI are extended beyon
Diagnosis of Latent Tuberculosis Infection
Tuberculin Skin Testing
Administering and reading tests. The tuberculin test, like all medical tests, is subject to variability, but many of the inherent vari intradermal, or Mantoux, method. It is administered by injecting 0.1 ml of 5 tuberculin units (TU) PPD intradermally into the do recorded in millimeters. Multiple puncture tests (i.e., Tine and Heaf) and PPD strengths of 1 TU and 250 TU are not sufficiently Interpreting skin-test reactions. Based on the sensitivity and specificity of the tuberculin skin test and the prevalence of TB in d induration (Table 7) . For persons who are at highest risk for developing TB disease if they become infected with M. tuberculosi systemic corticosteroids) have a high likelihood of developing TB disease if they are infected with M. tuberculosis. Likewise, pe are at high risk for TB. Thus, to ensure that persons at highest risk are evaluated and appropriately treated, the sensitivity provid A reaction of >10 mm of induration should be considered positive for those persons with an increased probability of recent infec users) ( Table 7 ). In addition to those groups listed, high-prevalence populations identified by analysis of local epidemiologic da Routine tuberculin testing is not recommended for populations at low risk for LTBI. However, if these persons are tested (e.g., a >15 mm is recommended. Skin-test conversion. For persons with negative tuberculin skin-test reactions who undergo repeat skin testing (e.g., health care w with M. tuberculosis. Previous vaccination with BCG. Tuberculin skin testing is not contraindicated for persons who have been vaccinated with BCG method can reliably distinguish tuberculin reactions caused by vaccination with BCG from those caused by natural mycobacteri tested is at increased risk for recent infection or has medical conditions that increase the risk for disease (Table 7) .
Anergy testing in persons infected with HIV. Anergy testing is not recommended for routine use in persons who are infected wit Chest Radiographs
A chest radiograph is indicated for all persons being considered for treatment of LTBI to exclude active pulmonary TB. Childre radiographs; additional radiographs should be performed at the physician's discretion. Because of the risk for progressive and/or persons with infectious TB disease should have chest radiographs (with appropriate shielding) as soon as feasible, even during t If chest radiographs are normal and no symptoms consistent with active TB are present, tuberculin-positive persons may be cand medical evaluation, bacteriologic examinations, and a comparison of the current and old chest radiographs) should be done to de Sputum Examinations Sputum examination is not indicated for most persons being considered for treatment of LTBI. However, persons with chest rad submitted for AFB smear and culture. Most persons with radiographs that show only calcified pulmonary nodules do not require sputum specimens submitted for mycobacterial examination, even if the chest radiograph is normal. If the results of sputum sme bacteriologic results are negative but the activity or etiology of a radiographic abnormality is questionable, further evaluation wi excluded. In such situations, multidrug therapy can be started and continued pending results of sputum cultures. A repeat chest f
Treatment of Latent Tuberculosis Infection
Individual Drugs
Isoniazid. Isoniazid is the most widely used of the antituberculosis agents---it is bactericidal, relatively nontoxic, easily adminis µg/ml). Absorption from the gastrointestinal tract is nearly complete, with peak serum concentrations of 2--5 µg/ml occurring 0. those found in serum. Hepatitis is the most severe toxic effect of isoniazid, and alcohol consumption may increase toxicity (Tab at a dose of 5 mg/kg. In persons with conditions in which neuropathy is common (e.g., diabetes, uremia, alcoholism, malnutritio pyridoxine and isoniazid. Mild central nervous system effects are common with isoniazid and may necessitate adjustments in th both drugs. When these drugs are given concomitantly, the serum level of phenytoin should be monitored. No known interaction Rifampin. Rifampin is a rifamycin derivative that is bactericidal for M. tuberculosis. Most strains of M. tuberculosis are inhibite occurring 1.5--3.0 h after ingestion. Although approximately 75% of the drug is protein bound, it penetrates well into tissues and are inflamed. The most common adverse reaction to rifampin is gastrointestinal upset. Other reactions include skin eruptions, he enzymes, it may accelerate clearance of drugs metabolized by the liver (e.g., methadone, coumadin derivatives, glucocorticoids, metabolism of estrogen, rifampin may interfere with the effectiveness of oral contraceptives. In persons with HIV infection who increased rifampin levels and decreased protease-inhibitor levels, resulting in increased risk for rifampin toxicity and decreased nucleoside reverse transcriptase inhibitors (NNRTIs). Intermittent administration of doses of rifampin >10 mg/kg may be associ the recommended dose of 10 mg/kg/d. Rifampin is excreted in urine, tears, sweat, and other body fluids and colors them orange Pyrazinamide. Pyrazinamide is bactericidal for M. tuberculosis in an acid environment. The drug is active against organisms in for M. tuberculosis is 20 µg/ml. Absorption from the gastrointestinal tract is nearly complete, with peak serum concentrations of gastrointestinal upset (Table 8 ). The most severe adverse reaction is liver injury. No substantial increase in hepatotoxicity result but acute gout is uncommon (127) . No known interactions exist between pyrazinamide and antiretroviral medications. Rifabutin. Rifabutin is another rifamycin that is highly active against M. tuberculosis. Its mechanism of action is the same as tha of 0.1 µg/ml. A dose of 300 mg results in peak serum concentrations of 5 µg/ml after 23 h. The major advantage of rifabutin is t metabolized in the liver (and to a lesser extent in the intestinal wall); only 8% of a dose is excreted unchanged in the urine. Dose myalgias, and dysguesia. Hepatotoxicity is rare, but rifabutin can cause drug-induced hepatitis. Rates of side effects increase wh uveitis (128) and abnormal skin pigmentation (129) . Similar to rifampin, rifabutin can also decrease concentrations and clinical dapsone, ketoconazole, and cyclosporin, as well as itraconazole, ß-blockers, and theophylline. Doses of these medications may h infection, may lead to increased levels of rifabutin and decreased levels of the protease inhibitor; however, these effects are gene infection, may also necessitate rifabutin dose adjustment.
Treatment Regimens
Treatment of LTBI is an essential part of the strategy to eliminate TB in the United States. Persons with LTBI who are included as detailed in the following sections.
U.S. Public Health Service Rating System. To help clinicians make informed treatment decisions based on the most current rese
The ratings system is similar to that used in previous PHS documents (3) and includes a letter and a Roman numeral: the letter i clinicians can use the ratings to differentiate between recommendations based on data from clinical trials and those based on the available). Recommended regimens. Four regimens are recommended for the treatment of adults with LTBI (Table 10) . The antituberculosi weekly treatment should receive DOT, because nonadherence to intermittent dosing results in a larger proportion of the total do institutional settings, community outreach programs, and for some persons living in households with patients who are receiving Isoniazid for 9 mo. The isoniazid daily regimen for 9 mo receives an A recommendation. Prospective, randomized trials of up t benefit is gained by extending treatment to 12 mo. Thus, this updated recommendation represents a shortening of the previous re uninfected persons (1) . Both 12-mo and 6-mo regimens of isoniazid have substantially reduced rates of TB in HIV-infected pers the recommendation for 9 mo of isoniazid in HIV-infected persons is based on extrapolation of available data. Intermittent dosin for active TB (where twice-weekly dosing is equivalent to daily dosing), twice-weekly dosing of isoniazid is also acceptable for Isoniazid for 6 mo. Although a 9-mo regimen of isoniazid is the preferred treatment of LTBI for an individual patient, a 6-mo r persons (32, 84) . From a societal perspective, treatment for 6 mo rather than 9 mo may provide a more cost-effective outcome (8 of a 6-mo rather than a 9-mo course of isoniazid. Isoniazid for 6 mo, taken either daily or twice weekly, is recommended at the B with radiographic evidence of prior tuberculosis. Rifampin and pyrazinamide for 2 mo. The 2-mo daily regimen of rifampin and pyrazinamide is recommended on the basis of efficacy to a 12-mo regimen of isoniazid (111) . Although this regimen has not been evaluated in HIV-uninfected persons with L at the A level for HIV-infected persons and at the B level for HIV-uninfected persons until further data are available. Two rando persons (86, 110) ; in neither case was the sample size adequate to conclude with certainty that efficacy was equivalent to daily d rifampin and pyrazinamide given twice weekly for 2--3 mo may be considered when alternative regimens cannot be given. This Rifampin for 4 mo. Rifampin given daily for 3 mo has resulted in better protection than placebo in treatment of LTBI in HIV-u active TB (4%), experts have concluded that a 4--mo regimen would be more prudent when using rifampin alone. This 4-mo rifa cannot tolerate isoniazid or pyrazinamide.
Choice of regimen. Because more than one regimen can be used to treat LTBI, health care providers should discuss options with include the length and complexity of the regimens, possible adverse effects, and potential drug interactions.
Completion of treatment.
Completion of therapy is based on total number of doses administered---not on duration of therapy alo in therapy. The 6-mo regimen of isoniazid should consist of at least 180 doses administered within 9 mo. Twice-weekly isoniazi The daily regimen of rifampin (or rifabutin) and pyrazinamide should consist of at least 60 doses to be administered within 3 mo Ideally, patients should receive medication on a regular dosing schedule until completion of the indicated course. However, in p clinicians might need to continue the regimen originally prescribed (as long as needed to complete the recommended duration o recommended. In either situation, when therapy is restored after an interruption of more than 2 mo, a medical examination to ru Special considerations. Treatment of HIV-infected persons. Recommendations for HIV-infected adults largely parallel those for HIV-uninfected adul LTBI in persons with HIV infection, 9 mo is recommended rather that 6 mo. In addition, rifampin is generally contraindicated o infected persons who are candidates for treatment of LTBI and need PI or NNRTI therapy, rifabutin can be substituted for rifam saquinavir, or delavirdine. Caution is advised if rifabutin is administered with soft-gel saquinavir, because data regarding use of No specific data have been generated for treatment of LTBI with rifabutin-containing regimens, but such a recommendation is s studies in mice (107,130). Rifabutin can be administered at one half the usual daily dose (i.e., reduced from 300 mg to 150 mg/d daily rifabutin dose is 450 mg or 600 mg when used with efavirenz; pharmacokinetic studies suggest that rifabutin might be giv likely more complex; in such situations, the use of rifabutin is not recommended until additional data are available. The substitu with HIV (131) . Furthermore, the drug interactions between rifapentine and HIV protease inhibitors have not been studied in de together (132). In tuberculin-negative, HIV-infected persons, treatment of LTBI has not been effective (3). However, most tuberculin-negative ended is not indicative of LTBI. Furthermore, some experts recommend treatment of possible LTBI for HIV-infected residents o Persons with fibrotic lesions/suspected disease. For patients who have a chest radiograph demonstrating old fibrotic lesions th treatment for TB, three acceptable regimens can be used for treatment. These regimens include 9 mo of isoniazid, 2 mo of rifam unlikely. Patients who begin multidrug therapy for suspected pulmonary TB but are subsequently determined not to have active rifampin and pyrazinamide if the tuberculin skin test is positive and other causes of the radiographic abnormalities have been ex Persons with evidence suggestive of healed, primary TB (i.e., calcified solitary pulmonary nodules, calcified hilar lymph nodes, consideration of other risk factors and the size of the tuberculin reaction (Table 7) . Pregnancy and lactation. Pregnancy has minimal influence on the pathogenesis of TB or the likelihood of LTBI progressing to have not demonstrated an effect of pregnancy on cutaneous delayed hypersensitivity to tuberculin (136, 137) . The current classi women. There is no evidence that the tuberculin skin test has adverse effects on the pregnant mother or fetus (138) . Pregnant women should be targeted for tuberculin skin testing only if they have a specific risk factor for LTBI or for progressio is more controversial. Some experts prefer to delay treatment until after delivery because pregnancy itself does not increase the hepatotoxicity (91, 92). However, because conditions that promote hematogenous spread of organisms to the placenta (e.g., rece pregnant women with these conditions and LTBI should be treated during pregnancy and have careful clinical and laboratory m consequences to both the mother and her child should active disease develop. Extensive use of isoniazid during pregnancy has indicated that although it readily crosses the placental barrier, the drug is not te utero to rifampin had abnormalities (i.e., limb reductions, central nervous system abnormalities, and hypoprothrombinemia) com the use of rifampin in the mother (141) . However, extensive experience with the use of rifampin to treat TB in pregnant women concerning the effects of the drug on the fetus. Thus, although pyrazinamide may be considered after the first trimester in wome The preferred regimen for treatment of LTBI in pregnant women is isoniazid, administered either daily or twice weekly. Althou are infected with HIV or who have been infected recently, initiation of therapy should not be delayed on the basis of pregnancy Pregnant women taking isoniazid should receive pyridoxine supplementation. Toxic effects of antituberculosis drugs delivered in breast milk have not been reported. One study concluded that a breastfeeding antituberculosis drugs (143). Breastfeeding is not contraindicated when the mother is being treated for LTBI. However, infants w inadequate for treatment of the infant. Children and adolescents. Several fundamental aspects of the natural history and treatment of LTBI in children must be consid infected recently, and are at high risk for progression to disease. Data suggest that untreated infants with LTBI have up to a 40% than older children and adults to develop life-threatening forms of TB, especially meningeal and disseminated disease. Children with several large clinical trials demonstrating risk reduction of 7090% (145, 146) . The risk for isoniazid-related hepatitis is min use in children. Because of differences in pathogenesis of TB infection and disease in children compared with adults, informatio trials of treatment of LTBI in children have studied isoniazid alone. The only recommended regimen for treatment of LTBI in HIV-uninfected children is a 9-mo course of isoniazid as self-adminis considered in children at risk for hepatic disease. When children taking antituberculosis therapy develop hepatitis, a search for c recommended for children taking isoniazid, but should be given to (1) breastfeeding infants, (2) children and adolescents with d Isoniazid given twice weekly has been used extensively to treat LTBI in children, especially schoolchildren and close contacts o definitively. DOT should be considered when it is unlikely that the child and family will be adherent to daily self-administration In the United States, rifampin alone has been used for the treatment of LTBI in infants, children, and adolescents when isoniazid (149) . However, no controlled clinical trials have been conducted. A 3-mo regimen of rifampin and isoniazid has been used in E rifampin and pyrazinamide therapy in children with LTBI, although a randomized study involving a limited number of children No studies have been published regarding the efficacy of any form of treatment for LTBI in HIV-infected children. The Americ liver enzyme concentrations be performed and pyridoxine given when HIV-infected children are treated with isoniazid. The opt treatment (150) .
Contacts of patients with tuberculosis.
• Contacts of patients with drug-susceptible tuberculosis. Persons who are contacts of patients with drug-susceptible TB (Table 10 ). In addition, some tuberculin-negative contacts should be considered for treatment. Because of susceptibility contact has ended. If the repeat skin test is positive, treatment should continue for the recommended period of time; if t contacts of persons with active TB should also receive treatment, even if repeat skin testing does not indicate LTBI.
• Contacts of patients with isoniazid-resistant tuberculosis. No definitive data exist concerning treatment of contacts who to recommend either rifampin alone or in combination with isoniazid or ethambutol when the risk of isoniazid-resistant with isoniazid-resistant TB (152) . In an outbreak of isoniazid-and streptomycin-resistant TB among homeless persons, six (9%) of 71 persons with skin tests that who received rifampin or isoniazid and rifampin (153) . Similarly, of 157 high school students who took rifampin after being exp rifampin prophylaxis failure was reported among contacts of a case patient with isoniazid-resistant TB in a community outbreak For contacts of patients with isoniazid-resistant, rifampin-susceptible TB, a 2-mo regimen of rifampin and pyrazinamide is recom cannot be used, rifabutin can be substituted.
• Contacts of patients with multidrug-resistant tuberculosis. The occurrence of outbreaks of multidrug-resistant TB (MD focused attention on options for treatment of persons exposed to and presumed to be infected by such organisms (155). failed to achieve consensus on the management of such persons (156) . Persons infected with isoniazid-and rifampin-resistant organisms are unlikely to benefit from treatment with regimens containin selection of drugs for such a regimen should be guided by in vitro susceptibility test results from the isolate to which the patient For persons who are likely to be infected with MDR TB and at high risk of developing TB, pyrazinamide and ethambutol or pyr are known to be susceptible to these agents (157). Immunocompetent contacts may be observed without treatment or treated for fluoroquinolones include gastrointestinal symptoms and hepatic transaminase elevations (158) . All persons with suspected MDR exposed to patients with MDR TB. No studies have been published regarding treatment of LTBI in children following exposure to multidrug-resistant TB. Ethambu susceptible to both drugs. Long-term use of fluoroquinolones in children should be avoided. Deleterious effects on growing cart of children with cystic fibrosis treated with ciprofloxacin or ofloxacin (161) . When pyrazinamide and ethambutol cannot be used Low-risk tuberculin test reactors. When treatment of LTBI is being considered for persons who are at low risk for developing vulnerable contacts (e.g., infants and HIV-infected persons) if treatment were not given and the patient were to develop active T therapy, treatment for LTBI is not usually appropriate. BCG-vaccinated persons. A history of BCG vaccination, with or without a BCG scar, should not influence the decision regard Directly observed therapy and measures to increase adherence. Any regimen that is given intermittently (i.e., twice weekly) given by DOT, which, for ease of administration, may consist of five observed and two self-administered doses each week. Patients with the highest priority for DOT are those at the highest risk of progression from latent to active TB, including persons used for the treatment of household contacts of patients receiving DOT for active TB and for treatment observed by staff membe If it is not possible to provide DOT to enhance adherence with treatment of LTBI, the prescribed regimen should be incorporate explain in simple, clear language what LTBI is, the health threat it presents, and how it is eradicated. Patients should be encoura necessary. Each visit between patient and medical provider during therapy is an opportunity to reinforce the patient's understand In addition to education about potential drug toxicity, patients should be told about common side effects and counseled on drug on an empty stomach, and salicylic acid can be used for symptomatic treatment of arthralgia caused by pyrazinamide.) Most interventions to improve adherence require substantial financial resources. Providing flexible clinic hours, reducing waitin expenses. Even the least intensive approaches to improve adherence increase program costs. The costs of these approaches to im recent infection or those persons at high risk for progression to active TB, if infected. In addition, programs should invest in app patients to accept and to complete treatment is necessary to achieve the full potential of this intervention to protect persons from Pretreatment Evaluation and Monitoring of Treatment Pretreatment evaluation. The pretreatment evaluation of persons who are targeted for treatment of LTBI provides an opportunit treatment and the importance of adherence to the drug regimen, d) review possible adverse effects of the regimen, including inte primary language with assistance of qualified medical interpreters, if necessary. The patient history should document risk factors for TB, prior treatment for TB or LTBI, and preexisting medical conditions tha and previous drug therapy should be obtained, with particular attention to previous adverse reactions to drugs contemplated for contraceptives are at increased risk for becoming pregnant and should be advised to consider an additional form of contraception each patient. Baseline laboratory testing is not routinely indicated for all patients at the start of treatment for LTBI (Table 8) . Patients whose i Baseline testing is also indicated for patients infected with HIV, pregnant women and those in the immediate postpartum period alcohol regularly, and others who are at risk for chronic liver disease. Baseline testing is no longer routinely indicated in persons medications for chronic medical conditions. Active hepatitis and end-stage liver disease are relative contraindications to the use Monitoring of treatment. Clinical monitoring is indicated for all patients; this involves education of patients about the symptoms evaluation should symptoms occur. These include any of the following: unexplained anorexia, nausea, vomiting, dark urine, icte (especially right upper quadrant discomfort), easy bruising or bleeding, and arthralgia (Table 8) . Clinical monitoring begins at th providers immediately upon the onset of such symptoms or any unexplained illness occurring during treatment.
Patients being treated for LTBI should receive a clinical evaluation, including a brief physical assessment checking for signs of 8). These evaluations represent opportunities to review the indications for treatment, adherence with therapy since the last visit, questionnaire may facilitate those interviews. Routine laboratory monitoring during treatment of LTBI is indicated for patients whose baseline liver function tests are abnorma symptoms compatible with hepatotoxicity or a uric acid measurement to evaluate patients who develop acute arthritis) should be patient's transaminase level exceeds 3 times the upper limit of normal if associated with symptoms and five times the upper limi Reporting of serious adverse events. Practitioners and other health professionals should report serious adverse events associated with hospitalization, permanent disability, or death. Reporting may be by mail, telephone (1-800-FDA-1088), fax (1-800-FDA-0
PRIORITIES FOR FUTURE RESEARCH Diagnosis
The only widely available method to detect LTBI is the tuberculin skin test. However, the specificity of the test is decreased by low, the test's positive predictive value is poor. In addition, the requirement that the person tested return for the test to be read 48 persons at greatest risk for progressing to active disease. Especially useful would be tests that distinguish skin-test reactions cau of living organisms, and tests that accurately identify LTBI in immunodeficient persons.
Operational Research
Acceptability, Tolerability, and Effectiveness of Daily Rifampin and Pyrazinamide
More data are needed regarding the acceptability, tolerability, and effectiveness of the 2-mo regimen of daily rifampin and pyraz Intermittent Rifampin-containing Regimens No studies of rifampin alone taken twice weekly for the treatment of LTBI have been conducted. Data from two studies in HIVeffective (86, 110) . Before additional trials of intermittent rifampin regimens are undertaken, animal model data are needed to co Isoniazid Taken Twice Weekly It is unlikely that a formal efficacy study of intermittent isoniazid for the treatment of LTBI will be undertaken, unless it is inclu regimen. Data from these programs should be examined, especially as they relate to acceptability and completion of treatment. T Studies in Children and Pregnant Women Studies are needed to provide information regarding the use of newer regimens for the treatment of LTBI in children and pregna hepatotoxicity of isoniazid in pregnant and postpartum women. Studies are needed to establish the safety and effectiveness of ri studies would be HIV-infected children in places in which TB is prevalent and household contacts of TB case patients. In additi effectiveness of alternative therapies for MDR LTBI in children are needed. Finally, epidemiologic research to determine the be Reporting and Monitoring in New Settings These recommendations call for the establishment of LTBI treatment programs in new community settings (e.g., managed care o settings other than health departments. These studies should assess the knowledge base of treating clinicians and identify the ob Combination Rifampin and Pyrazinamide Preparations If field and programmatic data establish the effectiveness and acceptability of the rifampin and pyrazinamide regimen for the tre of combination products in preventing the emergence of drug resistance in patients with active TB is not as compelling for perso medication for 2 wk of treatment for several different body weights) would be useful.
Efficacy Studies of New Drugs
No novel compounds currently can be considered candidates for the treatment of LTBI. However, several rifamycin derivatives experimental studies involving mice, the combination of rifapentine and isoniazid given once weekly for 3 mo was as active as r could be dosed less frequently without compromising efficacy (166) . The class of nitroimidazole compounds is also of interest b preclinical evaluation of new drugs.
Studies of Immunomodulators and Vaccines
Recent studies have indicated that immunotherapy with specific cytokines and immunomodulators may be beneficial to respons of certain cytokines (e.g., interferon gamma) may protect against the development of active TB. If further studies support this fi postinfection vaccine to be administered to persons with LTBI has been given high priority (168) .
